(Source: UCB SA) FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months Brussels, Belgium, Thousand Oaks, Calif, 22 February 2016 - 07:00am (CET) -regulated information - UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through months 12 and 24 in postmenopausal women with osteoporosis treated with romosozumab. The study also met the secondary endpoint of reducing the incidence of clinical...
↧